Halozyme Therapeutics (HALO) Tops Q2 EPS by 14c, Offers Guidance

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.74, $0.14 better than the analyst estimate of $0.60. Revenue for the quarter came in at $221 million versus the consensus estimate of $199.95 million.

GUIDANCE:

Halozyme Therapeutics sees FY2023 EPS of $2.65-$2.75, versus the consensus of $2.61. Halozyme Therapeutics sees FY2023 revenue of $825-845 million, versus the consensus of $823 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• The Lovesac Company (LOVE) Tops Q1 EPS by 29c
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance